B&M Gates and VCs hold $45.5m series-D for Arsanis

The foundation was joined by a consortium of new and existing VC investors in the round. GV (previously Google Ventures) and Alexandria Venture Investments backed the company for the first time, while Orbimed, Polaris Venture Partners, SV Health Investors, Neomed, EMBL Ventures and the Anna Maria and Stephen Kellen Foundation all reinvested.

The new funding will be used to focus efforts on the phase II study for ASN100, a standard of care for prevention of a specific type of pneumonia. It will also advance pre-clinical development operations, which are conducted in Vienna.

Previous funding
Prior to the latest round, Arsanis had raised $45m since 2010. In February 2011, Orbimed, Polaris and SV Life Sciences invested $10m in a series-A round for the company. Then in September 2013 the same group along with Neomed provided a further $20m in a series-B round. Finally, SV Life Sciences led a series-C for a further $15m in April 2016.

Company
Established in 2010, Arsanis is a biotechnology company dedicated to the development of anti-infective monoclonal antibody therapeutics. The company is based in Vienna, Austria, and is a wholly owned subsidiary of its US parent, Arsanis Inc.

People
Orbimed – Carl Gordon (co-head).
Arsanis – Rene Russo (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Austria
• Venture
• Polaris Private Equity
• Neomed Innovations